Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to $9.0 million.

  • Zevra Therapeutics' Other Accumulated Expenses rose 86666.67% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 86666.67%. This contributed to the annual value of $3.2 million for FY2024, which is 423.45% up from last year.
  • Zevra Therapeutics' Other Accumulated Expenses amounted to $9.0 million in Q3 2025, which was up 86666.67% from $6.9 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Other Accumulated Expenses high stood at $9.0 million for Q3 2025, and its period low was $7000.0 during Q1 2022.
  • In the last 5 years, Zevra Therapeutics' Other Accumulated Expenses had a median value of $1.3 million in 2021 and averaged $2.1 million.
  • Per our database at Business Quant, Zevra Therapeutics' Other Accumulated Expenses tumbled by 9807.69% in 2022 and then soared by 421428.57% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Other Accumulated Expenses stood at $836000.0 in 2021, then decreased by 14.0% to $719000.0 in 2022, then soared by 326.98% to $3.1 million in 2023, then grew by 4.23% to $3.2 million in 2024, then skyrocketed by 180.94% to $9.0 million in 2025.
  • Its Other Accumulated Expenses was $9.0 million in Q3 2025, compared to $6.9 million in Q2 2025 and $3.4 million in Q1 2025.